COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01733160
Recruitment Status : Completed
First Posted : November 26, 2012
Last Update Posted : October 27, 2017
Information provided by (Responsible Party):
Canadian Collaborative Research Network

Brief Summary:
This observational registry will characterize contemporary stroke prevention in Canadian adults with atrial fibrillation, and provide clarity in understanding physician preferences for the various oral anticoagulants available in the Canadian marketplace. This study will determine the patient profiles of those selected for the various therapies available in Canada and provide an understanding of the factors involved in drug selection and management.

Condition or disease
Cardiovascular Diseases

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 2499 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: SPRINT-AF: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation
Study Start Date : November 2013
Actual Primary Completion Date : August 15, 2017
Actual Study Completion Date : August 15, 2017

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. To determine how Canadian physicians assess stroke risk in adults with atrial fibrillation and make therapeutic decisions around anticoagulation [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. To assess the adequacy of anticoagulation in treated patients [ Time Frame: 1 year ]
  2. To understand how new oral anticoagulants are incorporated into clinical practice [ Time Frame: 1 year ]
  3. To assess quality of life in patients with AF [ Time Frame: 1 year ]
  4. To evaluate how physicians select between rate and rhythm control options for AF [ Time Frame: 1 year ]
  5. To evaluate regional differences in care [ Time Frame: 1 year ]
  6. To compare management strategies between primary care physicians and cardiovascular specialists [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care and specialist clinics

Inclusion Criteria:

  • Documented atrial fibrillation (ECG, rhythm strip, device interrogation, discussion of an AF diagnosis in the participant's clinical report) within the past 10 years; paroxysmal, persistent or permanent
  • Age > 18 years
  • Most recent visit for a patient having had a clinical visit with Investigator occurring within the past one year

Exclusion Criteria:

  • Valvular AF (hemodynamically significant valvular heart disease including rheumatic mitral valve disease or at least moderate aortic valve stenosis)
  • Life expectancy < 12 months
  • Active malignancy (treated or untreated)
  • Indication for systemic anticoagulation independent of atrial fibrillation (venous thromboembolism, mechanical heart valve)
  • Prior participation in any OAC randomized clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01733160

Layout table for location information
Canada, Ontario
Brampton, Ontario, Canada, L6Z 4N5
Sponsors and Collaborators
Canadian Collaborative Research Network
Layout table for investigator information
Principal Investigator: Milan K Gupta, MD Canadian Collaborative Research Network
Principal Investigator: Andrew Ha, MD Canadian Collaborative Research Network
Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Heuzey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011 Mar 15;123(10):1144-50. doi: 10.1161/CIR.0b013e31820f14c0. Epub 2011 Feb 14.

Layout table for additonal information
Responsible Party: Canadian Collaborative Research Network Identifier: NCT01733160    
Other Study ID Numbers: SPRINT-AF 18-10-2012
First Posted: November 26, 2012    Key Record Dates
Last Update Posted: October 27, 2017
Last Verified: October 2017
Keywords provided by Canadian Collaborative Research Network:
Atrial Fibrillation
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Cardiovascular Diseases
Arrhythmias, Cardiac
Heart Diseases
Pathologic Processes